Zoetis Inc. Announces Quarterly Dividend of $0.53 (NYSE:ZTS)

Zoetis Inc. (NYSE:ZTS) declared a quarterly dividend on Wednesday, May 20th. Stockholders of record on Monday, July 20th will be paid a dividend of 0.53 per share on Tuesday, September 1st. This represents a c) annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend is Monday, July 20th.

Zoetis has increased its dividend payment by an average of 0.2%per year over the last three years and has raised its dividend annually for the last 14 consecutive years. Zoetis has a dividend payout ratio of 31.0% indicating that its dividend is sufficiently covered by earnings. Analysts expect Zoetis to earn $7.42 per share next year, which means the company should continue to be able to cover its $2.12 annual dividend with an expected future payout ratio of 28.6%.

Zoetis Price Performance

Shares of NYSE ZTS opened at $79.64 on Thursday. The stock has a market cap of $33.39 billion, a PE ratio of 13.21, a price-to-earnings-growth ratio of 1.29 and a beta of 0.87. Zoetis has a fifty-two week low of $72.38 and a fifty-two week high of $172.23. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15. The stock has a fifty day moving average of $109.69 and a 200-day moving average of $119.37.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). The company had revenue of $2.26 billion during the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. Zoetis’s revenue for the quarter was up 2.9% compared to the same quarter last year. During the same quarter last year, the firm posted $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Equities research analysts anticipate that Zoetis will post 6.88 earnings per share for the current year.

Insider Transactions at Zoetis

In other news, Director Frank A. Damelio acquired 6,650 shares of the business’s stock in a transaction dated Wednesday, May 13th. The stock was purchased at an average cost of $75.39 per share, for a total transaction of $501,343.50. Following the acquisition, the director owned 21,458 shares of the company’s stock, valued at $1,617,718.62. This trade represents a 44.91% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Paul Bisaro acquired 2,000 shares of the business’s stock in a transaction dated Wednesday, May 13th. The stock was purchased at an average price of $75.88 per share, with a total value of $151,760.00. Following the completion of the acquisition, the director directly owned 27,862 shares in the company, valued at approximately $2,114,168.56. This represents a 7.73% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders bought 11,650 shares of company stock worth $886,384. 0.22% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Zoetis

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Nordea Investment Management AB lifted its position in shares of Zoetis by 79.2% in the fourth quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock valued at $622,222,000 after acquiring an additional 2,179,578 shares in the last quarter. CIBC Asset Management Inc lifted its position in shares of Zoetis by 4.3% in the third quarter. CIBC Asset Management Inc now owns 251,495 shares of the company’s stock valued at $36,745,000 after acquiring an additional 10,434 shares in the last quarter. Seilern Investment Management Ltd lifted its position in shares of Zoetis by 361.2% in the fourth quarter. Seilern Investment Management Ltd now owns 333,465 shares of the company’s stock valued at $41,957,000 after acquiring an additional 261,155 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in shares of Zoetis by 134.4% in the fourth quarter. Assenagon Asset Management S.A. now owns 1,631,619 shares of the company’s stock valued at $205,290,000 after acquiring an additional 935,432 shares in the last quarter. Finally, Mitsubishi UFJ Trust & Banking Corp lifted its position in shares of Zoetis by 6.5% in the third quarter. Mitsubishi UFJ Trust & Banking Corp now owns 295,482 shares of the company’s stock valued at $43,235,000 after acquiring an additional 18,040 shares in the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.